TORONTO, ONTARIO–(Marketwired – Sept. 12, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued US Patent 8,530,429 protecting its peptide technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
The patent protects novel synthetic peptides that target and attach to human BTICs and IGCs. The issuance of this patent gives Arch protection for Arch’s technology in the most important pharmaceutical market in the world. Arch anticipates similar patents will be issued in the rest of the world’s major pharmaceutical markets in due course.
This patent is based on technology invented by Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn at the University of Calgary.
About Malignant Glioma
There are approximately 70,000 new patients with malignant glioma each year in the developed world and clinical outcomes for these patients have not changed substantially over the past 30 years. Average survival rates remain at a dismal 12-15 months and long term survivors are rare.
This poor survival rate is linked to BTICs and invasive glioma cells which represent disease reservoirs that are not detectable using current diagnostic techniques as they are indiscernible from normal tissue. As a result, these cells are usually left behind in brain tissue post surgery and often lead to tumour relapse and poor patient outcomes.
Therefore, a significant unmet medical need and commercial opportunity is the ability to target BTICs and IGCs for the purpose of imaging, diagnosing and developing targeted therapies to improve patient outcomes and survival rates.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company’s lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma. The Company’s website address is: www.archbiopartners.com.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.